Pharmacological management in children and adolescents with pervasive developmental disorder

被引：8
|
作者：
Sung, Min [1 ]
Fung, Daniel S. S.
Cai, Yiming
Ooi, Yoon Phaik
机构：
[1] Inst Mental Hlth, Dept Child & Adolescent Psychiat, Singapore, Singapore
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | 2010年 / 44卷 / 05期
关键词：
Asperger's syndrome; autism; autism spectrum disorder; pervasive developmental; disorder; pharmacological management; AUTISTIC SPECTRUM DISORDERS; CONTROLLED-RELEASE MELATONIN; OPEN-LABEL TRIAL; DOUBLE-BLIND; RETROSPECTIVE ANALYSIS; REPETITIVE BEHAVIORS; DIVALPROEX SODIUM; PLACEBO; SYMPTOMS; NALTREXONE;
D O I：
10.3109/00048670903493330
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Methods: Electronic literature searches were conducted from the following sources: MEDLINE, Cochrane Library, PSYARTICLES and PsycINFO. Search terms included, but were not limited to, 'autism', 'PDD', 'autism spectrum disorder' ('ASD'), and 'pharmacological management'. Results: A range of pharmacological agents are available for the management of various dysfunctional symptoms in PDD. Broadly speaking, these agents help in the management of repetitive stereotyped behaviours, anxiety, aggression/irritability/self-injurious behaviour, hyperactivity/inattention and in sleep. Conclusions: There is a paucity of systemic, well-conducted trials on the use of pharmacological agents in the management of PDD, and more research in this area is warranted.
引用
收藏
页码：410 / 428
页数：19
相关论文
共 50 条
12345